Drug Profile

PMC 402

Alternative Names: PMC-402

Latest Information Update: 10 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PharmAbcine
Class Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
Mechanism of Action TIE-2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 May 2022 PharmAbcine plans to submit IND for Cancer in third quarter of 2022 (PharmAbcine pipeline, May 2022)
19 May 2020 PharmAbcine plans to initiate IND enabling studies in year 2020
05 Apr 2020 PharmAbcine plans a phase I trial for Cancer in 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com